Literature DB >> 27440205

Expression profiles of miR-29c, miR-200b and miR-375 in tumour and tumour-adjacent tissues of head and neck cancers.

Kristyna Hudcova1,2,3, Martina Raudenska1,2,3, Jaromir Gumulec1,2,3, Hana Binkova4, Zuzana Horakova4, Rom Kostrica4, Petr Babula1, Vojtech Adam3,5, Michal Masarik6,7,8.   

Abstract

Altered expression of microRNAs (miRNAs) has been shown in many types of malignancies including the head and neck squamous cell carcinoma (HNSCC). Although there are many new and innovative approaches in the treatment of HNSCC, a clear marker of this disease is still missing. Three candidate miRNAs (miR-29c-3p, miR-200b-5p and miR-375-3p) were studied in connection with HNSCC using quantitative real-time PCR expression levels in 42 tissue samples of HNSCC patients and histologically normal tumour-adjacent tissue samples of these patients. Primary HNSCC carcinoma tissues can be distinguished from histologically normal-matched noncancerous tumour-adjacent tissues based on hsa-miR-375-3p expression (sensitivity 87.5 %, specificity 65 %). Additionally, a significant decrease of hsa-miR-200b-5p expression was revealed in tumour-adjacent tissue samples of patients with node positivity. Lower expression of hsa-miR-200b-5p and hsa-miR-29c-3p in HNSCC tumour tissue was associated with higher tumour grade. Consequently, survival analysis was performed. Lower expression of hsa-miR-29c-3p in tumour-adjacent tissue was associated with worse overall and disease-specific survivals. Lower expression of miR-29c-3p in tumourous tissue was associated with worse relapse-free survival. hsa-miR-375-3p seems to be a relatively promising diagnostic marker in HNSCC but is not suitable for prognosis of patients. Furthermore, this study highlighted the importance of histologically normal tumour-adjacent tissue in HNSCC progress (significant decrease of hsa-miR-200b-5p expression in tumour-adjacent tissue of patients with node positivity and low expression of hsa-miR-29c-3p in HNSCC tumour-adjacent tissue associated with worse prognosis).

Entities:  

Keywords:  Biomarkers, tumour; Carcinoma, squamous cell of head and neck; Head and neck neoplasms; MicroRNAs; Proportional hazards models; Survival

Mesh:

Substances:

Year:  2016        PMID: 27440205     DOI: 10.1007/s13277-016-5147-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  32 in total

1.  Stressed tumor cell, chemosensitized cancer.

Authors:  Erik A C Wiemer
Journal:  Nat Med       Date:  2011-12-06       Impact factor: 53.440

2.  miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42.

Authors:  Seong-Yeon Park; Jung Hyun Lee; Minju Ha; Jin-Wu Nam; V Narry Kim
Journal:  Nat Struct Mol Biol       Date:  2008-12-14       Impact factor: 15.369

Review 3.  Revisiting the principles of microRNA target recognition and mode of action.

Authors:  Peter Brodersen; Olivier Voinnet
Journal:  Nat Rev Mol Cell Biol       Date:  2009-01-15       Impact factor: 94.444

4.  A core microRNA signature associated with inducers of the epithelial-to-mesenchymal transition.

Authors:  Juan Díaz-Martín; Antonio Díaz-López; Gema Moreno-Bueno; M Ángeles Castilla; Juan M Rosa-Rosa; Amparo Cano; José Palacios
Journal:  J Pathol       Date:  2014-02       Impact factor: 7.996

5.  MiR-29c suppresses invasion and metastasis by targeting TIAM1 in nasopharyngeal carcinoma.

Authors:  Na Liu; Ling-Long Tang; Ying Sun; Rui-Xue Cui; Hui-Yun Wang; Bi-Jun Huang; Qing-Mei He; Wei Jiang; Jun Ma
Journal:  Cancer Lett       Date:  2012-11-08       Impact factor: 8.679

6.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.

Authors:  Jacques Ferlay; Hai-Rim Shin; Freddie Bray; David Forman; Colin Mathers; Donald Maxwell Parkin
Journal:  Int J Cancer       Date:  2010-12-15       Impact factor: 7.396

Review 7.  Increase in head and neck cancer in younger patients due to human papillomavirus (HPV).

Authors:  David Young; Christopher C Xiao; Benjamin Murphy; Michael Moore; Carole Fakhry; Terry A Day
Journal:  Oral Oncol       Date:  2015-06-09       Impact factor: 5.337

8.  MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma.

Authors:  H J Bae; J H Noh; J K Kim; J W Eun; K H Jung; M G Kim; Y G Chang; Q Shen; S-J Kim; W S Park; J Y Lee; S W Nam
Journal:  Oncogene       Date:  2013-06-03       Impact factor: 9.867

9.  MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins.

Authors:  Srikumar Sengupta; Johan A den Boon; I-How Chen; Michael A Newton; Stephen A Stanhope; Yu-Juen Cheng; Chien-Jen Chen; Allan Hildesheim; Bill Sugden; Paul Ahlquist
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-04       Impact factor: 11.205

10.  Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer.

Authors:  Lyndsay V Rhodes; Elizabeth C Martin; H Chris Segar; David F B Miller; Aaron Buechlein; Douglas B Rusch; Kenneth P Nephew; Matthew E Burow; Bridgette M Collins-Burow
Journal:  Oncotarget       Date:  2015-06-30
View more
  19 in total

1.  The microRNA-375 as a potentially promising biomarker to predict the prognosis of patients with head and neck or esophageal squamous cell carcinoma: a meta-analysis.

Authors:  Peng Wang; LiangLiang Xu; Lian Li; ShengSheng Ren; JianWei Tang; Ming Zhang; MingQing Xu
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-02-12       Impact factor: 2.503

2.  Identification of potential core genes in gastric cancer using bioinformatics analysis.

Authors:  Changjiang Shao; Rong Wang; Dandan Kong; Qian Gao; Chunfang Xu
Journal:  J Gastrointest Oncol       Date:  2021-10

3.  Aberrant miR-10b, miR-372, and miR-375 expression in the cytobrushed samples from oral potentially malignant disorders.

Authors:  Hsi-Feng Tu; Kuo-Wei Chang; Shu-Chun Lin; Wan-Wen Hung; Si-Hua Ji; Hsiao-Li Wu; Chung-Ji Liu
Journal:  J Dent Sci       Date:  2021-07-30       Impact factor: 3.719

4.  hsa-miR-29c-3p regulates biological function of colorectal cancer by targeting SPARC.

Authors:  Shitong Zhang; Jianjun Jin; Xiaoxiao Tian; Lijuan Wu
Journal:  Oncotarget       Date:  2017-11-10

5.  Serum miR-200c and miR-371-5p as the Useful Diagnostic Biomarkers and Therapeutic Targets in Kawasaki Disease.

Authors:  Wei Zhang; Yan Wang; Yiwen Zeng; Liyi Hu; Guotao Zou
Journal:  Biomed Res Int       Date:  2017-06-01       Impact factor: 3.411

6.  eNOS expression and NO release during hypoxia is inhibited by miR-200b in human endothelial cells.

Authors:  Anna Janaszak-Jasiecka; Anna Siekierzycka; Sylwia Bartoszewska; Marcin Serocki; Lawrence W Dobrucki; James F Collawn; Leszek Kalinowski; Rafal Bartoszewski
Journal:  Angiogenesis       Date:  2018-05-08       Impact factor: 9.596

7.  Prognostic Value of miRNAs in Head and Neck Cancers: A Comprehensive Systematic and Meta-Analysis.

Authors:  Chellan Kumarasamy; Madurantakam Royam Madhav; Shanthi Sabarimurugan; Sunil Krishnan; Siddhartha Baxi; Ajay Gupta; K M Gothandam; Rama Jayaraj
Journal:  Cells       Date:  2019-07-25       Impact factor: 6.600

8.  Tissue and serum microRNA profile of oral squamous cell carcinoma patients.

Authors:  Augusto Schneider; Berta Victoria; Yury Nunez Lopez; Wiktoria Suchorska; Wojciech Barczak; Agnieszka Sobecka; Wojciech Golusinski; Michal M Masternak; Pawel Golusinski
Journal:  Sci Rep       Date:  2018-01-12       Impact factor: 4.379

9.  Micro-ribonucleic acids and extracellular vesicles repertoire in the spent culture media is altered in women undergoing In Vitro Fertilization.

Authors:  Masood Abu-Halima; Sebastian Häusler; Christina Backes; Tobias Fehlmann; Claudia Staib; Sigrun Nestel; Irina Nazarenko; Eckart Meese; Andreas Keller
Journal:  Sci Rep       Date:  2017-10-19       Impact factor: 4.379

10.  The circular RNA 001971/miR-29c-3p axis modulates colorectal cancer growth, metastasis, and angiogenesis through VEGFA.

Authors:  Chen Chen; Zhiguo Huang; Xiaoye Mo; Yanmin Song; Xiangmin Li; Xiaogang Li; Mu Zhang
Journal:  J Exp Clin Cancer Res       Date:  2020-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.